Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma
NCT ID: NCT03248128
Last Updated: 2025-06-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
906 participants
INTERVENTIONAL
2017-10-20
2022-03-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma
NCT02446418
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
NCT05757102
A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma
NCT02924688
An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma
NCT02301975
An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma
NCT01706198
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Subjects receiving FF/VI in cohort A
Subjects will be randomized in 1:1 ratio to receive a FDC of FF/VI with a dose of 50/25 mcg administered once daily in the morning via ELLIPTA DPI.
FF/VI via ELLIPTA DPI
ELLIPTA DPI inhaler will contain two individual blister strips; the first strip will contain FF(50 or 100 mcg) and second strip will contain VI (25 mcg).
Subjects receiving FF in cohort A
Subjects will be randomized in 1:1 ratio to receive FF with a dose of 50 mcg administered once daily in the morning via ELLIPTA DPI.
FF via ELLIPTA DPI
ELLIPTA DPI inhaler will contain a single blister strip of FF (50 or 100 mcg).
Subjects receiving FF/VI in cohort B
Subjects will be randomized in 1:1 ratio to receive a FDC of FF/VI with a dose of 100/25 mcg administered once daily in the morning via ELLIPTA DPI.
FF/VI via ELLIPTA DPI
ELLIPTA DPI inhaler will contain two individual blister strips; the first strip will contain FF(50 or 100 mcg) and second strip will contain VI (25 mcg).
Subjects receiving FF in cohort B
Subjects will be randomized in 1:1 ratio to receive FF with a dose of 100 mcg administered once daily in the morning via ELLIPTA DPI.
FF via ELLIPTA DPI
ELLIPTA DPI inhaler will contain a single blister strip of FF (50 or 100 mcg).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FF/VI via ELLIPTA DPI
ELLIPTA DPI inhaler will contain two individual blister strips; the first strip will contain FF(50 or 100 mcg) and second strip will contain VI (25 mcg).
FF via ELLIPTA DPI
ELLIPTA DPI inhaler will contain a single blister strip of FF (50 or 100 mcg).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A history of symptoms consistent with a diagnosis of asthma for at least 6 months.
* Pre-bronchodilator FEV1 \>50 percent to \<=90 percent predicted normal. A minimum of 2 efforts that are considered acceptable (not necessarily repeatable) are required to be eligible.
* Lung function reversibility defined as an increase of \>=12 percent in FEV1 within 10 to 40 minutes following 2 to 4 inhalations of salbutamol inhalation aerosol (or 1 nebulized treatment with albuterol/salbutamol solution). Use of a spacer is permitted.
* Uncontrolled asthma, with a childhood asthma control test (cACT)/ACT score \<=19.
* Receiving stable asthma therapy (SABA inhaler plus ICS \[total daily dose \<=FP 250 micrograms (mcg) or equivalent\]) for at least 4 weeks prior to Visit 1 (i.e. screening).
* Able to replace their current SABA treatment with salbutamol aerosol inhaler at Visit 1 for use as needed for the duration of the study. Salbutamol metered dose inhaler (MDI) will be administered with or without a spacer, to be used as determined by the investigator. The use or non-use of the spacer should be consistent for an individual subject throughout the study.
* Male or female subjects will be included. Females of reproductive potential must agree to follow 1 of the options listed (which include abstinence) in the Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) from 30 days prior to the first dose of study medication and until at least five terminal half-lives or until any continuing pharmacologic effect has ended, whichever is longer after the last dose of study medication and completion of the follow-up call. The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception.
* Written informed consent from at least 1 parent/care giver (legal guardian) and accompanying informed assent from the subject (where the subject is able to provide assent) prior to admission to the study. If applicable, subject must be able and willing to give assent to take part in the study according to the local requirement. The study investigator is accountable for determining a child's capacity to assent to participation in a research study, taking into consideration any standards set by the responsible independent ethics committee (IEC); subject and their legal guardian(s) understand that the study requires them to be treated on an outpatient basis; subject and their legal guardian(s) understand that they must comply with study medication and study assessments including recording of PEF and rescue SABA use, attending scheduled study visits, and being accessible by a telephone call.
* For subjects eligible for randomization; asthma control: uncontrolled asthma, with a cACT/ACT score \<=19.
* A technically acceptable pre-bronchodilator FEV1 \>50 percent to \<=90 percent predicted normal at Visit 2. A minimum of 2 efforts that are considered acceptable and repeatable following the over read are required to be eligible.
* Symptoms and rescue use: demonstrated and reported in a daily diary symptoms of asthma (a score of \>=1 on the day-time or night-time asthma symptom scores) and/or daily albuterol/salbutamol on at least 3 of the last 7 consecutive days of the run-in period (not including the date of randomization).
* Compliance with run-in medication: compliance is defined as use of run-in medication on at least 4 of the last 7 consecutive days of the run-in period (not including the date of randomization) recorded in the electronic subject diary.
* Compliance with completion of the daily diary reporting: defined as completion of all questions on 4 out of the last 7 days during the run-in period (not including the date of randomization).
Exclusion Criteria
* Any asthma exacerbation requiring the use of oral steroids within 6 weeks of Visit 1, systemic or depot corticosteroids within 12 weeks of Visit 1, or ER attendance within 3 months of Visit 1 or hospitalization within 6 months of Visit 1.
* A culture documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that has not resolved within 4 weeks of Visit 1 and which led to a change in asthma management or, in the opinion of the investigator, is expected to affect the subject's asthma status or the subject's ability to participate in the study.
* Clinical visual evidence of oropharyngeal candidiasis.
* Fasting blood glucose at screening \>100 milligrams/deciliter (mg/dL) (5.6 moles per liter \[mol/L\]).
* Obesity (Body Mass Index \[BMI\] above the 97th centile based on the centers for disease control and prevention \[CDC\] charts).
* Any significant abnormality or medical condition identified at the screening medical assessment (including serious psychological disorder) that in the investigator's opinion, preclude entry into the study due to risk to the subject or that may interfere with the conduct and/or outcome of the study.
* QTc \>450 milliseconds (msec) or QTc \>480 msec in subjects with bundle branch block or any other clinically significant abnormality in the screening 12-lead ECG.
* Use of any prohibited medications.
* Present use of any tobacco products.
* Drug allergies: any adverse reaction including immediate or delayed hypersensitivity to any beta 2-agonists, sympathomimetic drug or any intranasal, inhaled, or systemic corticosteroid therapy. Known or suspected sensitivity to the constituents of the ELLIPTA Inhaler (i.e. lactose or magnesium stearate).
* Milk Protein Allergy: history of severe milk protein allergy.
* Participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, five half-lives or twice the duration of the biological effect of the study treatment (whichever is longer).
* Exposure to more than 4 investigational medicinal products within 12 months prior to the first dosing day.
* An affiliation with the investigator site: the parents/guardians or child is an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator.
* The parent or guardian has a history of psychiatric disease, intellectual deficiency, substance abuse or other condition (example, inability to read, comprehend or write) which may affect: validity of consent to participate in the study; adequate supervision of the subject during the study; compliance of subject with study medication and study procedures (example, completion of daily diary, attending scheduled clinic visits); subject safety and well-being.
* Children in care: children who are wards of the government or state are not eligible for participation in this study.
* For subjects eligible for randomization; Changes in asthma medication that occur after screening.
* Occurrence of a culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear during the run-in period that led to a change in asthma management or, in the opinion of the investigator, is expected to affect the subject's asthma status or the subject's ability to participate in the study.
* Evidence of an exacerbation, defined as a: deterioration of asthma requiring the use of oral corticosteroids for at least 3 days, or a depot corticosteroid injection, or an in-patient hospitalization due to asthma that required systemic corticosteroids between screening and randomization.
* Clinical visual evidence of oropharyngeal candidiasis at the randomization Visit.
* Unable to use the ELLIPTA inhaler correctly.
5 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Hoover, Alabama, United States
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Huntington Beach, California, United States
GSK Investigational Site
Riverside, California, United States
GSK Investigational Site
Colorado Springs, Colorado, United States
GSK Investigational Site
Denver, Colorado, United States
GSK Investigational Site
Denver, Colorado, United States
GSK Investigational Site
Aventura, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami Lakes, Florida, United States
GSK Investigational Site
Ocala, Florida, United States
GSK Investigational Site
Orlando, Florida, United States
GSK Investigational Site
Orlando, Florida, United States
GSK Investigational Site
Gainesville, Georgia, United States
GSK Investigational Site
Savannah, Georgia, United States
GSK Investigational Site
Evanston, Illinois, United States
GSK Investigational Site
Oak Park, Illinois, United States
GSK Investigational Site
Evansville, Indiana, United States
GSK Investigational Site
Owensboro, Kentucky, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
White Marsh, Maryland, United States
GSK Investigational Site
Ypsilanti, Michigan, United States
GSK Investigational Site
Piscataway, New Jersey, United States
GSK Investigational Site
Verona, New Jersey, United States
GSK Investigational Site
Great Neck, New York, United States
GSK Investigational Site
New Hartford, New York, United States
GSK Investigational Site
Asheville, North Carolina, United States
GSK Investigational Site
Charlotte, North Carolina, United States
GSK Investigational Site
Raleigh, North Carolina, United States
GSK Investigational Site
Grove City, Ohio, United States
GSK Investigational Site
Oklahoma City, Oklahoma, United States
GSK Investigational Site
Medford, Oregon, United States
GSK Investigational Site
Wexford, Pennsylvania, United States
GSK Investigational Site
Greenville, South Carolina, United States
GSK Investigational Site
Orangeburg, South Carolina, United States
GSK Investigational Site
Spartanburg, South Carolina, United States
GSK Investigational Site
Summerville, South Carolina, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Lewisville, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Waco, Texas, United States
GSK Investigational Site
Murray, Utah, United States
GSK Investigational Site
Berazategui, Buenos Aires, Argentina
GSK Investigational Site
CABA, Buenos Aires, Argentina
GSK Investigational Site
CABA, Buenos Aires, Argentina
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
GSK Investigational Site
Florida, Buenos Aires, Argentina
GSK Investigational Site
La Plata, Buenos Aires, Argentina
GSK Investigational Site
Lanús, Buenos Aires, Argentina
GSK Investigational Site
Lobos, Buenos Aires, Argentina
GSK Investigational Site
Mar del Plata, Buenos Aires, Argentina
GSK Investigational Site
Nueve de Julio, Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Mendoza, , Argentina
GSK Investigational Site
Rosario, , Argentina
GSK Investigational Site
Santa Fe, , Argentina
GSK Investigational Site
Rousse, , Bulgaria
GSK Investigational Site
Sofia, , Bulgaria
GSK Investigational Site
Sofia, , Bulgaria
GSK Investigational Site
Stara Zagora, , Bulgaria
GSK Investigational Site
Brampton, Ontario, Canada
GSK Investigational Site
Windsor, Ontario, Canada
GSK Investigational Site
Québec, , Canada
GSK Investigational Site
Panzhihua, Sichuan, China
GSK Investigational Site
Taiyuan, , China
GSK Investigational Site
Heidelberg, Baden-Wurttemberg, Germany
GSK Investigational Site
Mannheim, Baden-Wurttemberg, Germany
GSK Investigational Site
Rosenheim, Bavaria, Germany
GSK Investigational Site
Geesthacht, Schleswig-Holstein, Germany
GSK Investigational Site
Budapest, , Hungary
GSK Investigational Site
Budapest, , Hungary
GSK Investigational Site
Szeged, , Hungary
GSK Investigational Site
Parma, Emilia-Romagna, Italy
GSK Investigational Site
Rome, Lazio, Italy
GSK Investigational Site
Bergamo, Lombardy, Italy
GSK Investigational Site
Milan, Lombardy, Italy
GSK Investigational Site
Milan, Lombardy, Italy
GSK Investigational Site
Palermo, Sicily, Italy
GSK Investigational Site
Ancona, The Marches, Italy
GSK Investigational Site
Perugia, Umbria, Italy
GSK Investigational Site
Chiba, , Japan
GSK Investigational Site
Fukui, , Japan
GSK Investigational Site
Fukuoka, , Japan
GSK Investigational Site
Fukuoka, , Japan
GSK Investigational Site
Hiroshima, , Japan
GSK Investigational Site
Hokkaido, , Japan
GSK Investigational Site
Hokkaido, , Japan
GSK Investigational Site
Hyōgo, , Japan
GSK Investigational Site
Kanagawa, , Japan
GSK Investigational Site
Osaka, , Japan
GSK Investigational Site
Tokyo, , Japan
GSK Investigational Site
Tokyo, , Japan
GSK Investigational Site
Tokyo, , Japan
GSK Investigational Site
Tokyo, , Japan
GSK Investigational Site
Tokyo, , Japan
GSK Investigational Site
Tokyo, , Japan
GSK Investigational Site
Vilnius, , Lithuania
GSK Investigational Site
Guadalajara, Jalisco, Mexico
GSK Investigational Site
Guadalajara, Jalisco, Mexico
GSK Investigational Site
Zapopan, Jalisco, Mexico
GSK Investigational Site
Monterrey, Nuevo León, Mexico
GSK Investigational Site
Monterrey, Nuevo León, Mexico
GSK Investigational Site
Villahermosa, Tabasco, Mexico
GSK Investigational Site
Bialystok, , Poland
GSK Investigational Site
Bialystok, , Poland
GSK Investigational Site
Bydgoszcz, , Poland
GSK Investigational Site
Częstochowa, , Poland
GSK Investigational Site
Katowice, , Poland
GSK Investigational Site
Krakow, , Poland
GSK Investigational Site
Lodz, , Poland
GSK Investigational Site
Lodz, , Poland
GSK Investigational Site
Ostrowiec Świętokrzyski, , Poland
GSK Investigational Site
Ostrów Wielkopolski, , Poland
GSK Investigational Site
Poznan, , Poland
GSK Investigational Site
Skierniewice, , Poland
GSK Investigational Site
Strzelce Opolskie, , Poland
GSK Investigational Site
Tarnów, , Poland
GSK Investigational Site
Warsaw, , Poland
GSK Investigational Site
Wroclaw, , Poland
GSK Investigational Site
Zawadzkie, , Poland
GSK Investigational Site
Brasov, , Romania
GSK Investigational Site
Brasov, , Romania
GSK Investigational Site
Bucharest, , Romania
GSK Investigational Site
Bucharest, , Romania
GSK Investigational Site
Bucharest, , Romania
GSK Investigational Site
Târgu Mureş, , Romania
GSK Investigational Site
Krasnodar, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Omsk, , Russia
GSK Investigational Site
Penza, , Russia
GSK Investigational Site
Perm, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Samara, , Russia
GSK Investigational Site
Saransk, , Russia
GSK Investigational Site
Saratov, , Russia
GSK Investigational Site
St'Petersburg, , Russia
GSK Investigational Site
Tomsk, , Russia
GSK Investigational Site
Ufa, , Russia
GSK Investigational Site
Volgograd, , Russia
GSK Investigational Site
Voronezh, , Russia
GSK Investigational Site
Yaroslavl, , Russia
GSK Investigational Site
Boksburg, Gauteng, South Africa
GSK Investigational Site
Johannesburg, Gauteng, South Africa
GSK Investigational Site
Pretoria, Gauteng, South Africa
GSK Investigational Site
Pretoria, Gauteng, South Africa
GSK Investigational Site
Middelburg, Mpumalanga, South Africa
GSK Investigational Site
Panorama, Western Province, South Africa
GSK Investigational Site
Bellville, , South Africa
GSK Investigational Site
Bloemfontein, , South Africa
GSK Investigational Site
Cape Town, , South Africa
GSK Investigational Site
Durban, , South Africa
GSK Investigational Site
eMkhomazi, , South Africa
GSK Investigational Site
Pretoria, , South Africa
GSK Investigational Site
Somerset West, , South Africa
GSK Investigational Site
Soweto, , South Africa
GSK Investigational Site
Vosloorus Ext 2, , South Africa
GSK Investigational Site
Badalona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bareille P, Forth R, Imber V, Bondarenko I, Michaud A, Majorek-Olechowska B. Once-daily fluticasone furoate/vilanterol vs once-daily fluticasone furoate in patients with asthma aged 5 to 17 years. Ann Allergy Asthma Immunol. 2024 Nov;133(5):537-544.e4. doi: 10.1016/j.anai.2024.06.024. Epub 2024 Jun 25.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-004086-87
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
107116
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.